Short Interest in Integral Ad Science Holding Corp. (NASDAQ:IAS) Rises By 8.5%

Integral Ad Science Holding Corp. (NASDAQ:IAS) was the target of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 5,370,000 shares, a growth of 8.5% from the October 31st total of 4,950,000 shares. Currently, 7.3% of the shares of the stock are short sold. Based on an average daily volume of 792,700 shares, the days-to-cover ratio is presently 6.8 days.

Integral Ad Science Trading Up 3.2 %

NASDAQ:IAS traded up $0.36 on Monday, hitting $11.54. 1,067,153 shares of the stock were exchanged, compared to its average volume of 1,370,252. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of 57.55, a P/E/G ratio of 1.54 and a beta of 1.52. Integral Ad Science has a 52 week low of $7.98 and a 52 week high of $17.53. The company’s 50-day moving average price is $11.09 and its 200 day moving average price is $10.59. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.71 and a current ratio of 3.71.

Integral Ad Science (NASDAQ:IAS) last posted its earnings results on Tuesday, November 12th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.02. The company had revenue of $133.50 million during the quarter, compared to analyst estimates of $138.06 million. Integral Ad Science had a return on equity of 3.47% and a net margin of 6.39%. The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.09) EPS. On average, equities research analysts forecast that Integral Ad Science will post 0.26 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on IAS. Oppenheimer dropped their target price on Integral Ad Science from $20.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, November 13th. Benchmark reiterated a “hold” rating on shares of Integral Ad Science in a report on Thursday, November 14th. Piper Sandler dropped their price objective on Integral Ad Science from $18.00 to $16.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. Barclays increased their price objective on Integral Ad Science from $12.00 to $13.00 and gave the stock an “equal weight” rating in a report on Monday, August 5th. Finally, Truist Financial dropped their price objective on Integral Ad Science from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.70.

Insider Buying and Selling

In other Integral Ad Science news, CFO Tania Secor sold 5,240 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $10.11, for a total value of $52,976.40. Following the completion of the sale, the chief financial officer now directly owns 248,223 shares of the company’s stock, valued at approximately $2,509,534.53. This represents a 2.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Lisa Utzschneider sold 10,481 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $10.11, for a total transaction of $105,962.91. Following the completion of the sale, the chief executive officer now directly owns 239,709 shares of the company’s stock, valued at $2,423,457.99. The trade was a 4.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,006 shares of company stock valued at $240,296 over the last 90 days. 2.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Integral Ad Science

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of Integral Ad Science by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 8,673,229 shares of the company’s stock valued at $86,472,000 after purchasing an additional 566,982 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Integral Ad Science in the 2nd quarter valued at approximately $4,724,000. Nisa Investment Advisors LLC grew its position in shares of Integral Ad Science by 449,805.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 427,410 shares of the company’s stock valued at $4,154,000 after purchasing an additional 427,315 shares during the period. abrdn plc grew its position in shares of Integral Ad Science by 12.5% in the 3rd quarter. abrdn plc now owns 2,147,656 shares of the company’s stock valued at $23,216,000 after purchasing an additional 237,930 shares during the period. Finally, Invenomic Capital Management LP grew its position in shares of Integral Ad Science by 57.4% in the 3rd quarter. Invenomic Capital Management LP now owns 585,309 shares of the company’s stock valued at $6,327,000 after purchasing an additional 213,488 shares during the period. 95.78% of the stock is currently owned by institutional investors and hedge funds.

Integral Ad Science Company Profile

Integral Ad Science Holding Corp. operates as a digital advertising verification company in the United States, the United Kingdom, France, Ireland, Germany, Italy, Singapore, Australia, Japan, India, and the Nordics. The company provides IAS Signal, a cloud-based technology platform that offers return on ad spend needs; and deliver independent measurement and verification of digital advertising across devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video.